The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2023 | Stereotactic radiotherapy vs surgery in early-stage NCSLC
Paul Van Schil, MD, PhD, University Hospital Antwerp, Edegem, Belgium, offers his perspective on the longstanding debate regarding whether stereotactic radiotherapy or surgery is more efficacious in the treatment of patients with early-stage non-small cell lung cancer (NCSLC). Although Dr Van Schil believes treatment decisions should be made on the distinction of whether patients are functionally operable or inoperable, he emphasizes the capacity of sub lobal resections to provide accurate nodal staging and to determine precise tumor histology. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
